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Abstract
Nontypeable Haemophilus influenzae (NTHi) is an opportunistic pathogen which causes a variety of respiratory infections.
The objectives of the study were to determine its antimicrobial susceptibility, to characterize the b-lactam resistance, and to
establish a genetic characterization of NTHi isolates. Ninety-five NTHi isolates were analyzed by pulsed field gel
electrophoresis (PFGE) and multi locus sequence typing (MLST). Antimicrobial susceptibility was determined by
microdilution, and the ftsI gene (encoding penicillin-binding protein 3, PBP3) was PCR amplified and sequenced. Thirty
(31.6%) isolates were non-susceptible to ampicillin (MIC$2 mg/L), with 10 of them producing b-lactamase type TEM-1 as a
resistance mechanism. After ftsI sequencing, 39 (41.1%) isolates showed amino acid substitutions in PBP3, with Asn526R
Lys being the most common (69.2%). Eighty-four patients were successfully treated with amoxicillin/clavulanic acid,
ceftriaxone and levofloxacin. Eight patients died due either to aspiration or complication of their comorbidities. In
conclusion, NTHi causing CAP in adults shows high genetic diversity and is associated with a high rate of reduced
susceptibility to ampicillin due to alterations in PBP3. The analysis of treatment and outcomes demonstrated that NTHi
strains with mutations in the ftsI gene could be successfully treated with ceftriaxone or fluoroquinolones.
Citation: Puig C, Calatayud L, Martı´ S, Tubau F, Garcia-Vidal C, et al. (2013) Molecular Epidemiology of Nontypeable Haemophilus influenzae Causing Community-
Acquired Pneumonia in Adults. PLoS ONE 8(12): e82515. doi:10.1371/journal.pone.0082515
Editor: Oliver Schildgen, Kliniken der Stadt Ko¨ln gGmbH, Germany
Received September 4, 2013; Accepted November 4, 2013; Published December 13, 2013
Copyright:  2013 Puig et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant from the Fondo de Investigaciones Sanitarias de la Seguridad Social (PI0901904), by CIBER de Enfermedades
Respiratorias (CIBERES - CB06/06/0037), run by the ISCIII (Instituto de Salud Carlos III), Madrid, Spain, and by Spanish Network for Research on Infectious Diseases
(REIPI, RD12/0015), run by ISCIII, Madrid, Spain. CP was supported by grants from AGAUR-FI (Generalitat de Catalunya, Spain) and from FPU (Formacio´n de
Profesorado Universitario, Ministerio de Educacio´n, Spain). SM was supported by a ‘‘Sara Borrell Postdoctoral Contract, CD10/00298’’ from the Instituto de Salud
Carlos III (ISCIII), Madrid, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: c.ardanuy@bellvitgehospital.cat
Introduction
Haemophilus influenzae is a human-restricted pathogen which
forms part of the normal nasopharyngeal microbiota [1–4]. This
bacterial species is commonly divided into two different groups
depending on the presence or absence of the polysaccharide
capsule, with six serotypes (a–f) currently described in the
encapsulated group. In children, serotype b (Hib) is responsible
for most invasive diseases, although incidence has dramatically
decreased since vaccine introduction [4]. Non-capsulated H.
influenzae, also known as nontypeable H. influenzae (NTHi),
colonizes asymptomatically the nasopharynx in healthy people,
and is also a frequent cause of otitis media, sinusitis, conjunctivitis,
community-acquired pneumonia (CAP) and exacerbations in
chronic obstructive pulmonary disease (COPD) [1–4].
CAP is a common respiratory infection which frequently
requires patient hospitalization. Current studies identify H.
influenzae as either the second most common pathogen causing
CAP, after Streptococcus pneumoniae [5,6], or the third most common
pathogen after S. pneumoniae and Mycoplasma pneumoniae [7]. In our
geographical area, H. influenzae has been identified as the
aetiological agent in 6–10% of CAP [8].
Aminopenicillin antibiotics have been used in the treatment of
H. influenzae infections, and as a result, mechanisms of resistance
against this group of antimicrobials have developed [9–11]. The
most common mechanism of b-lactam resistance involves the
production of a b-lactamase enzyme, usually TEM-1 type or,
more rarely, ROB-1 type [12]. Alterations in penicillin-binding
proteins (PBP3) have also been reported in different H. influenzae
strains [13,14]. This phenotype, also known as b-lactamase
negative ampicillin resistance (BLNAR), is related to mutations
in the ftsI gene (encoding the transpeptidase domain of PBP3) [15].
The frequency of resistance to other antimicrobials such as
quinolones or azithromycin is, however, low [11,16].
Epidemiological studies of individual patient groups are
important for determining the level and mechanisms of antimi-
crobial resistance. In line with this goal, the present study had
three main objectives: to determine the antimicrobial susceptibility
of nontypeable H. influenzae strains isolated from patients with non-
bacteremic CAP, to characterize the b-lactam resistance and to
establish the clonal relatedness among these strains.
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Materials and Methods
Ethics Statement
This work was approved by the ‘Comite´ E`tic d’Investigacio´
Clı´nica del Hospital Universitari de Bellvitge’ and the written or
oral informed consent was considered not necessary, because the
source of bacterial isolates was anonymized and the study was
retrospective.
Hospital Setting and Bacterial Strains
This study was carried out at the Hospital de Bellvitge in
Barcelona, a hospital for adults serving a population of ca. 600,000
people. A retrospective review of computerized medical charts was
performed in all patients seen at the hospital during the study
period in order to record those with CAP criteria. Pneumonia was
considered when a new infiltrate on a chest radiograph plus one
or more of the following symptoms were detected: fever or
hypothermia, new cough, pleuritic chest pain, dyspnea or altered
breath sounds on auscultation [8]. Overall mortality was defined
as death within 30 days of pneumonia diagnosis. Patients were
considered cured when clinical findings of pneumonia had
disappeared and there was radiological improvement.
A total of 95 NTHi isolates were collected from sputum samples
of 92 patients diagnosed with non-bacteremic CAP between 2000
and 2009.
Only H. influenzae isolates from good quality sputum samples
(,10 squamous cells and .25 leukocytes per low-power field) and
with a predominance of Gram negative coccobacilli forms were
considered [17].
Isolates were identified by conventional methodology and
preserved by cryopreservation. Additionally, all isolates were
identified by mass spectrometry using a MALDI-Biotyper version
3.0 (Bruker), following the manufacturer’s recommendations.
Differentiation between H. influenzae and H. haemolyticus was
performed by the detection of fucK, iga and lgtC genes using a
previously described methodology [18]. Isolates were identified as
H. influenzae if they were positive for the three tested genes.
Biotyping, Serotyping and Antimicrobial Susceptibility
Biotypes were determined using three biochemical reactions:
urease, indol and ornithine decarboxylase [19]. Serotyping was
achieved with the latex agglutination PhadebactH Haemophilus
Test (Bactus AB, Huddinge, Sweden) and by PCR as stipulated by
Falla et al. [20]. Antimicrobial susceptibility was determined by
microdilution according to the criteria of the Clinical Laboratory
Standards Institute (CLSI) [21,22]. b-lactamase production was
screened using the chromogenic cephalosporin method (nitrocefin
disks, BD, Madrid, Spain).
PCR and DNA Sequencing
Identification of b-lactamase type was performed by PCR on all
the b-lactamase positive isolates using primers and conditions
described previously [23]. For molecular characterization of PBP3,
an internal region of the ftsI gene (796–1741 pb) was amplified by
PCR and sequenced using previously described methodology [24].
Genotype Definition for Ampicillin Resistance
According to previous descriptions [25,26] and on the basis of
b-lactamase production and changes in the ftsI gene, H. influenzae
isolates were classified into four genotypes: b-lactamase negative
ampicillin susceptible (gBLNAS), strains without a detectable
resistance mechanism; b-lactamase negative ampicillin resistant
(gBLNAR), strains that did not produce a b-lactamase enzyme but
which presented mutations in the transpeptidase domain of the ftsI
gene; b-lactamase positive ampicillin resistant (gBLPAR), strains
producing b-lactamase but which did not present mutations in ftsI;
and b-lactamase positive amoxicillin/clavulanic acid resistant
(gBLPACR), strains which presented both resistance mechanisms
(b-lactamase production and mutations in the ftsI gene).
Molecular Typing
Pulsed field gel electrophoresis (PFGE). Strain relatedness
was determined by PFGE with the restriction enzyme SmaI (New
England BioLabs, Ipswich, MA, USA), as instructed by the
manufacturer. Molecular typing was performed on bacterial
suspensions of H. influenzae grown on chocolate agar plates, as
described by Dabernat et al. [24] but with some modifications.
Briefly, bacterial suspensions were prepared in PIV (10 mM Tris-
HCl [pH 8], 1 M NaCl) and adjusted to the same final
concentration. The bacterial suspension was mixed with an equal
volume of melted 1.5% low-melting point agarose (Life Technol-
ogies, Madrid, Spain) in order to prepare DNA-agarose plugs with
a volume of 20 ml each. These were incubated for 5 h at 37uC in
1 ml of ST buffer (6 mM Tris-HCl [pH 8]; 1 M NaCl; 0.1 M
EDTA [pH 8]) containing 0.5% Brij-58, 100 mg/mL lysozyme
and 50 mg/ml RNAse. The agarose plugs were transferred into ES
buffer (1 M EDTA, 1% sarcosyl) with 1 mg/mL proteinase K
(Sigma Aldrich, Madrid, Spain) and incubated over night at 50uC.
Finally, the plugs were rinsed three times at room temperature
with TE buffer (10 mM Tris-HCl [pH 8]; 1 mM EDTA [pH 8]).
The DNA-embedded plugs were digested with 5 U of SmaI for
18 h at 25uC. DNA fragments were then separated in a 1%
agarose gel (Megabase, BioRad) with 0.5% TBE buffer (45 mM
Tris-base, 45 mM boric acid, 1.0 mM EDTA pH 8.0) in a
contour-clamped homogenous electric field system (CHEF DR III;
BioRad). The gels were run for 19 h at 14uC, using a constant
voltage of 6 V/cm with an angle of 120u and an increasing pulse
time from 1 s to 30 s. A bacteriophage l, low-range PFG marker
(New England BioLabs, Ipswich, MA, USA) was used as a size
standard.
PFGE band patterns were analyzed using the Fingerprinting II
Software 3.0 (BioRad). The similarity of the PFGE banding
patterns was estimated with the Dice coefficient, setting the
optimization and tolerance at 1%. Isolates with $80% relatedness
were considered highly genetically related [27].
Multilocus sequence type (MLST). Clinical isolates were
analyzed by MLST in order to identify strain relatedness [28].
Allele number and sequence types (ST) were assigned using the H.
influenzae MLST website (http://haemophilus.mlst.net). The
overall database was analyzed using e-BURST v3 in order to
define groups available on the H. influenzae MLST website.
Results
Patient Characteristics and Antimicrobial Susceptibility
NTHi isolates were recovered from 95 episodes of CAP in 92
patients. Sixty-four patients (69.6%) were men and the mean age
was 68.15 years (SD614.39). Comorbid conditions were present
in 97% of patients, with COPD being the most frequent
underlying disease (28.3%), followed by chronic heart disease
(18.5%), malignancy (15.2%), diabetes mellitus (13%) and chronic
renal failure (4.3%). Finally, 59.7% of patients were either current
(13%) or past (46.7%) smokers.
Table 1 summarizes the antibiotic susceptibility of the NTHi
isolates. All of them were susceptible to ceftriaxone, cefotaxime
and levofloxacin. By contrast, 10.5% of the isolates were resistant
to ampicillin due to the expression of a TEM-1 b-lactamase, and
23.2% presented intermediate resistance. The rate of resistance to
Community-Acquired Pneumonia Due to NTHi
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cotrimoxazole was high (32.6%), whereas the frequency of
resistance to amoxicillin/clavulanic acid, cefuroxime, tetracycline,
chloramphenicol and azithromycin was low (,4%).
Mutation Patterns in the ftsI Gene
The sequence of ftsI encoding the transpeptidase region of PBP3
was determined in all the isolates. Table 2 summarizes the amino
acid changes observed, corresponding to 41.1% of the isolates.
The most common amino acid substitution was Asn526R Lys
(27/39, 69.2%), followed by Arg517R His (2/39, 5.1%). The
patterns observed were classified into groups I and II according to
the criteria of Dabernat et al. [24].
Two isolates were classified as Group I and presented the
Arg517R His substitution alone. Group II included 27 isolates
subdivided into three subgroups: i) 5 isolates belonged to the
subgroup IIa (1 isolate with Asn526R Lys, and the remaining 4
isolates with other mutations); ii) 7 isolates were classified as
subgroup IIb, defined by Asn526R Lys and Ala502R Val
substitutions (those isolates also presented the substitutions
Asp350R Asn and Met377R Ile, and one of them also had a
Gly490R Glu); iii) the subgroup IIc, characterized by Asn526R
Lys and Ala502R Thr substitutions, was the most common, with
15 isolates. No isolates were observed in subgroup IId or in groups
III and III-like (previously described by Garcı´a-Cobos et al. [10]).
Six patterns (10 isolates) were characterized and classified into
the miscellaneous group: four of them (6 isolates) have already
been described by Garcı´a-Cobos et al. [10], while the remaining
two were determined in this study and presented the Ala454R Val
and Asp350R Asn/Thr532R Asn substitutions.
Fourteen of 36 gBLNAR isolates (38.9%) presented ampicillin
MIC within the susceptibility range (#0.25–1 mg/L). All the
isolates with MIC #0.25 or 0.5 of ampicillin belonged to the
miscellaneous group, suggesting that these mutations were not
involved in decreased b-lactam susceptibility.
Phenotypic and Genotypic Characterization
Phenotypically, the most common biotype found was biotype II
(39.0%) followed by biotypes III (35.7%), I (16.8%), V (3.2%), VI
(3.2%) and IV (2.1%). As a result of positive detection of lgtC, fucK
and iga genes, all the isolates were identified as H. influenzae.
Molecular typing by PFGE revealed 47 different PFGE
patterns. Twenty-six patterns were genotypically unique and 21
clusters contained between 2 and 15 related isolates (.80%
similarity). Furthermore, molecular typing by MLST showed 67
different sequence types, with 28 of them (ST974, ST989 to
ST1000, ST1143, ST1162, ST1163, ST1171, ST1172, ST1174,
and ST1176 to ST1184) being described for the first time in the
present study. The most frequent ST was ST159 (7 isolates).
Analysis with e-BURST (including single and double locus
variants) revealed 11 groups ($2 isolates) and 29 singletons (only
1 isolate). Groups 1, 2 and 10 were the largest, with 9 isolates each
(Table S1, Supplementary data).
The 39 isolates with mutations in the ftsI gene were grouped
into 25 independent PFGE clusters. Despite the fact that most
patterns were unique, five clusters were identified with between
two and nine genetically-related isolates (.80% similarity)
(Figure 1). Cluster D grouped the majority of isolates with
alterations in PBP3 (n = 9), with five different ST: ST159 (n = 4),
ST819 (n = 2), ST201 (n = 1), ST414 (n = 1) and ST1177 (n = 1).
These nine clonally-related isolates were collected from different
patients throughout the study period. Six of these isolates were
grouped in the same e-BURST group (ST159/ST819). The
isolates in this cluster belonged to different amino acid substitution
groups: IIc (n = 4), IIb (n = 2), I (n = 2) and IIa (n = I). Cluster E
contained four isolates with three different ST: ST556 (n = 2),
ST388 (n = 1) and ST997 (n = 1). Two of these isolates belonged to
the miscellaneous group of amino acid substitutions, while the
remaining two isolates belonged to subgroups IIb and IIc,
respectively. The other three clusters (F, I and K) contained two
isolates each. The isolates in cluster F had the same ST (ST142)
and were classified into subgroups IIa and IIb. Cluster I comprised
isolates with ST1000 and ST1048, which belonged to the same
subgroup (IIc). Finally, cluster K was composed of isolates with
ST425 and ST998, which were grouped into subgroup IIa and the
miscellaneous amino acid substitution groups, respectively.
Treatment and Patient Outcomes
Antibiotic therapy and clinical outcomes were analyzed for all
patients included in this study. All patients were treated following
the recommendations of the Infectious Disease Society of America
and the guidelines of the American Thoracic Society [29].
Forty-one of 46 patients infected by gBLNAR, gBLPAR or
gBLPACR isolates were successfully treated, mainly with amox-
icillin/clavulanic acid, ceftriaxone and levofloxacin, or by using a
combination of two of these antibiotics. The remaining five
patients, infected by gBLNAR isolates, were treated with
amoxicillin/clavulanic acid and ceftriaxone but died, due to
aspiration, during the first 72 h of hospital admission (Table 3).
Forty-three of 46 patients infected by isolates with a genotype
susceptible to aminopenicillins (gBLNAS) were successfully treated
with ceftriaxone, amoxicillin/clavulanic acid and levofloxacin.
The remaining three patients died by aspiration or due to
complication of their severe underlying diseases (Table 3).
Discussion
H. influenzae is a common cause of CAP in adults (6–10%) [8]
and it is frequently associated with recurrent pneumonia in both
children and adults [8,30]. In this study, we analyzed the
Table 1. Minimal inhibitory concentrations (MIC) of 10
antimicrobials. MIC against 95 NTHi isolates using the
microdilution method according to CLSI breakpoints.
Antimicrobials MIC50 MIC90 Range
CLSIa
(mg/L) (mg/L) %I %R
Ampicillin 0.5 2 #0.25–
$16
23.2 10.5
Amoxicillin/
clavulanic acidb
1 4 #0.5–8 0 2.1
Ceftriaxone ,0.06 ,0.06 #0.06–
0.12
0 0
Cefotaxime ,0.06 ,0.06 #0,06–
0.12
0 0
Cefuroxime 2 4 #0.5–$8 3.1 1.1
Tetracycline #2 #2 #2–$4 0 2.1
Chloramphenicol #2 #2 #2–8 0 1.1
Azithromycin 2 2 #0.5–$4 0 1.1
Levofloxacin #0.5 #0.5 #0.5–1 0 0
Cotrimoxazolec #0.5 .2 #0.5–$2 0 32.6
aCLSI: Clinical and Laboratory Standards Institute. I: intermediate; R: resistant.
bThe ratio of amoxicillin/clavulanic acid was 2:1.
cThe ratio of cotrimoxazole was 1:19.
doi:10.1371/journal.pone.0082515.t001
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Figure 1. Tree diagram showing the genetic relatedness of 39 nontypeable H. influenzae isolates with mutations in the ftsI gene
(gBLNAR n=36 and gBLPACR n=3) obtained by PFGE according to Dice’s similarity index. Dice coefficients are shown above the tree
diagram. Isolates with $80% relatedness are considered highly genetically related.
doi:10.1371/journal.pone.0082515.g001
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molecular epidemiology of NTHi causing non-bacteremic CAP in
adult patients in the Barcelona area of Spain.
b-lactam antimicrobials are the first therapeutic option for
treating CAP due to H. influenzae [29]. Resistance to ampicillin
varies among European countries [31,32]. The rate of reduced
susceptibility to ampicillin found in this study was 33.7% (10.5% of
isolates were resistant and 23.2% presented intermediate resis-
tance), which is higher than the rate reported (16.2%) in a recent
Spanish study by Perez-Trallero et al. [16]. A possible explanation
for this high percentage of ampicillin non-susceptibility is that the
majority of NTHi isolates were obtained from elderly patients who
had received multiple antibiotic courses for their underlying
diseases.
b-lactamase are the most common mechanism through which
resistance to b-lactam antibiotics is acquired, although the
frequency of their involvement fluctuates depending on the
geographical area in question [33–35]. In our study, 10.5% of
isolates presented TEM-1 b-lactamase production. This result is
consistent with an overall downward trend that has been observed
in Spain (from 25.7% in 1997 to 15.7% in 2007 [16]), as well as in
other European countries and the USA [36]. However, different
rates of b-lactam resistance due to alterations in PBP3 have been
reported in several countries [15,24,36,37]. In the present study,
41.1% of isolates had amino acid substitutions in the transpep-
tidase domain of PBP3. The percentage of BLNAR isolates
detected in other European countries such as Germany (11.8%),
France (0%), Portugal (9.6%) and the UK (1.5%) is lower than that
found here [37]. The observed rate of gBLNAR could be due to
the fact that most of our patients with CAP received multiple
b-lactam antibiotic courses as treatment for their underlying
diseases. Furthermore, the consumption of aminopenicillins in
Catalonia increased from 46.1% in 1992 to 59.6% in 2007 [38],
and this could also explain the frequency of gBLNAR observed in
this study. In line with a previous report on Spanish isolates [10],
the most frequent mutation found in the ftsI gene was Asn526R
Lys, followed by Arg517R His, and this allowed us to use the
Dabernat et al. classification to group our isolates [24]. The
presence of these mutations conferred a reduced susceptibility
on ampicillin and amoxicillin/clavulanic acid (MIC between
1–4 mg/L) although those mutations alone were not enough to
confer full resistance. In this set of NTHi, no isolates were found to
belong to groups III or III-like (Met377R Ile and Ser385R Thr
substitutions), which have been related to decreased cefotaxime
and cefixime susceptibility [10].
Most of our patients infected with strains that were non-
susceptible to ampicillin were successfully treated with amoxicil-
lin/clavulanic acid, ceftriaxone or levofloxacin. In accordance
with other studies [16,31], amoxicillin/clavulanic acid, third-
generation cephalosporins and quinolones showed excellent in
vitro activity and are good therapeutic options for treating non-
bacteremic CAP due to NTHi. However, since no gBLNAR
isolates with ampicillin MIC $4 mg/L were found in our study,
the clinical outcomes of patients infected by strains with high
ampicillin MIC is unknown.
NTHi strains isolated from CAP episodes were found to be
genetically diverse, this being consistent with other surveillance
studies performed on respiratory or invasive NTHi isolates
[39,40]. Some studies carried out on BLNAR strains have
demonstrated the high genotypic heterogeneity and lack of clonal
spread in these strains [41,42]. However, recent studies suggest a
clonal dissemination of some BLNAR or BLPACR strains
[10,43,44]. In our study, some small clusters of gBLNAR strains
were found (Figure 1), but only one cluster, comprising two strains,
presented the same ftsI pattern, thereby suggesting a lack of clonal
distribution in NTHi from CAP patients.
In conclusion, this study has established the genotypic
characterization and antimicrobial resistance of NTHi causing
non-bacteremic CAP in adult patients. The results illustrate the
high genetic diversity among these strains, as well as the high rate
of reduced susceptibility to ampicillin due to alterations in PBP3.
Finally, the analysis of treatment and outcomes in this group of
patients demonstrated that NTHi strains with mutations in the ftsI
gene (gBLNAR and gBLPACR) could be successfully treated with
ceftriaxone or fluoroquinolones.
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